March 1, 2023, the Eli Lilly Biotech Center in San Diego, California.
Mike Blake | Reuters
Yililai On Thursday, the fourth quarter results were different as sales surged in its blockbuster weight loss Zepbough and Diabetes Drug Mounjaro, but were lower but lower.
The figures are consistent with preliminary results shared by Eli Lilly in January, which disappointed investors. Eli Lilly Cut its revenue guidance for 2024As it says, the need for weight loss and diabetes medications cannot meet its lofty expectations.
The company’s quarterly revenue exceeded Wall Street’s estimates, but sales were insufficient.
The pharmaceutical giant also released its fiscal 2025 profit guide, at $22.05 to $23.55 per share, in line with analyst expectations. Eli Lilly reiterated its fiscal 2025 sales guide to $58 billion to $6.1 billion.
According to LSEG’s survey of analysts, this is what Eli Lilly reported in the fourth quarter:
- Earnings per share: $5.32 adjusted with expected $4.95
- income: $13.53 billion vs. $13.57 billion
The company’s fourth-quarter revenue was $13.53 billion, up 45% from the same period a year ago.
In the fourth quarter, the pharmaceutical giant booked $4.41 billion in net income, or $4.88 per share. By comparison, profit a year ago was $2.19 billion, or $2.42 per share.
Excluding one-time items related to intangible asset value and other adjustments, Eli Lilly earned $5.32 per share in the fourth quarter of 2024.
This story is developing. Please check it for updates.
